Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elraglusib +/- Ruxolitinib in Advanced Myelofibrosis
NCT04218071Phase 2Completed
- Sponsor
- Actuate Therapeutics
- Start
- Aug 2020
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of elraglusib in myelofibrosis (MF) (2 arms), sponsored by Actuate Therapeutics. Primary endpoint: Response rate. Started Aug 2020; status: completed.
02
Drugs
elraglusib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT04218071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04218071.